Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se

Tregitopes are a set of epitopes, derived from IgG, that bind to MHCII, activate nTregs, and promote tolerance. We have now confirmed that coadministration of Tregitopes with a range of proteins (autoantigens and nominal antigens, such as OVA) in vitro and in vivo leads to suppression of T cell and antibody responses to the test antigens. In this study, we demonstrate that Tregitopes are not immunogenic in vivo even when emulsified with strong adjuvants, such as IFA or CFA. Moreover, in vivo administration of Tregitopes with IFA or CFA does not induce Th1 or Th2 cytokine expression under restimulation conditions in vitro. We investigated tolerance induction by codelivering Tregitopes with OVA using B cells. When B cells were pulsed with OVA plus Tregitopes and transferred into naïve mice, we found that cellular and humoral immune responses to the OVA were suppressed. As a result of their ability to induce Tregs and the absence of immunogenicity in the context of strong adjuvants, Tregitopes might be considered a novel immunomodulatory approach for the suppression of immune responses to protein therapeutics (such as FVIII and mAb), as well as for treatment of autoimmune diseases.

[1]  D. Scott,et al.  Application of IgG-Derived Natural Treg Epitopes (IgG Tregitopes) to Antigen-Specific Tolerance Induction in a Murine Model of Type 1 Diabetes , 2013, Journal of diabetes research.

[2]  Anne S De Groot,et al.  Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. , 2012, World journal of gastroenterology.

[3]  D. Scott,et al.  B-cell based gene therapy for autoimmune diseases. , 2012, Infectious disorders drug targets.

[4]  Mark J. Miller,et al.  T Cell Dynamics during Induction of Tolerance and Suppression of Experimental Allergic Encephalomyelitis , 2011, The Journal of Immunology.

[5]  D. Scott,et al.  Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis , 2011, Neurology research international.

[6]  D. Scott,et al.  B cells "transduced" with TAT-fusion proteins can induce tolerance and protect mice from diabetes and EAE. , 2011, Clinical immunology.

[7]  D. Scott,et al.  B-Cell Gene Therapy for Tolerance Induction: Host but Not Donor B-Cell Derived IL-10 is Necessary for Tolerance , 2011, Front. Microbio..

[8]  Aaron J. Martin,et al.  Current landscape for T-cell targeting in autoimmunity and transplantation. , 2011, Immunotherapy.

[9]  T. Ficht,et al.  Lipopolysaccharide-Deficient Brucella Variants Arise Spontaneously during Infection , 2011, Front. Microbio..

[10]  D. Scott,et al.  B-cell delivered gene therapy for tolerance induction: role of autoantigen-specific B cells. , 2010, Journal of autoimmunity.

[11]  D. Scott,et al.  Can we prevent immunogenicity of human protein drugs? , 2009, Annals of the rheumatic diseases.

[12]  D. Scott,et al.  Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". , 2008, Blood.

[13]  D. Scott,et al.  B Cells Induce Tolerance by Presenting Endogenous Peptide-IgG on MHC Class II Molecules via an IFN-γ-Inducible Lysosomal Thiol Reductase-Dependent Pathway1 , 2008, The Journal of Immunology.

[14]  J. Ravetch,et al.  Anti-inflammatory actions of intravenous immunoglobulin. , 2008, Annual review of immunology.

[15]  Qizhi Tang,et al.  The Foxp3+ regulatory T cell: a jack of all trades, master of regulation , 2008, Nature Immunology.

[16]  J. Ellis,et al.  Innocuous IFNγ induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production , 2008, The Journal of experimental medicine.

[17]  S. Kaveri,et al.  Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. , 2008, Blood.

[18]  D. Scott,et al.  Tolerance induction by gene transfer to lymphocytes. , 2007, Current gene therapy.

[19]  S. Kaveri,et al.  Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action , 2007, Nature Clinical Practice Rheumatology.

[20]  S. Kaveri,et al.  Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action , 2007, Journal of Clinical Immunology.

[21]  A. Rudensky,et al.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice , 2007, Nature Immunology.

[22]  D. Scott,et al.  Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. , 2006, Cellular immunology.

[23]  D. Scott,et al.  Mechanisms of Gene Therapy for Tolerance: B7 Signaling Is Required for Peptide-IgG Gene-Transferred Tolerance Induction1 , 2005, The Journal of Immunology.

[24]  D. Scott,et al.  Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. , 2005, Blood.

[25]  D. Scott,et al.  Tolerance induction via a B-cell delivered gene therapy-based protocol: optimization and role of the Ig scaffold. , 2005, Cellular immunology.

[26]  D. Scott,et al.  A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. , 2004, Clinical immunology.

[27]  H. Ochs,et al.  Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis , 2003, Current opinion in rheumatology.

[28]  T. Malek,et al.  CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. , 2002, Immunity.

[29]  D. Scott,et al.  Gene Transfer of Ig-Fusion Proteins Into B Cells Prevents and Treats Autoimmune Diseases1 , 2002, The Journal of Immunology.

[30]  J Bayry,et al.  Pathophysiology of inhibitors to factor VIII in patients with haemophilia A , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[31]  D. Scott,et al.  Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. , 2000, The Journal of clinical investigation.

[32]  D. Scott,et al.  Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Achiron,et al.  Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses , 1998, Neurology.

[34]  D. Scott,et al.  Both resting and activated B lymphocytes expressing engineered peptide-Ig molecules serve as highly efficient tolerogenic vehicles in immunocompetent adult recipients. , 1997, Journal of immunology.

[35]  D. Scott,et al.  Epitope-specific tolerance induction with an engineered immunoglobulin. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Scott,et al.  Tregitope update: mechanism of action parallels IVIg. , 2013, Autoimmunity reviews.

[37]  D. Scott,et al.  New approaches to enzyme replacement therapy for Pompe disease , 2012 .

[38]  M. Noris,et al.  Natural versus adaptive regulatory T cells. , 2005, Contributions to nephrology.

[39]  N. Gadoth,et al.  Intravenous immunoglobulin treatment in multiple sclerosis. , 1999, Neurology.